Uniphos Enterprises Limited (NSE:UNIENTER)
155.05
+2.57 (1.69%)
Aug 12, 2025, 3:30 PM IST
Orchard Therapeutics Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 160.7 | 29.86 | 14.96 | 16.26 | 43.18 | Upgrade |
Short-Term Investments | 1.05 | 440.1 | 302 | - | - | Upgrade |
Trading Asset Securities | - | - | 200.34 | 375.2 | 408.35 | Upgrade |
Cash & Short-Term Investments | 161.75 | 469.96 | 517.3 | 391.46 | 451.53 | Upgrade |
Cash Growth | -65.58% | -9.15% | 32.15% | -13.30% | 5.58% | Upgrade |
Accounts Receivable | - | 4.85 | - | - | - | Upgrade |
Other Receivables | 0.62 | 0.45 | 11.17 | 6.97 | 6.78 | Upgrade |
Receivables | 0.62 | 5.3 | 11.17 | 153.97 | 153.78 | Upgrade |
Prepaid Expenses | 0.27 | 0.15 | 0.17 | 0.22 | - | Upgrade |
Other Current Assets | - | 5.09 | 2.95 | 51.12 | 0.79 | Upgrade |
Total Current Assets | 162.63 | 480.49 | 531.59 | 596.77 | 606.1 | Upgrade |
Long-Term Investments | 26,155 | 18,025 | 28,363 | 30,428 | 25,092 | Upgrade |
Long-Term Deferred Tax Assets | - | 214.6 | - | - | - | Upgrade |
Other Long-Term Assets | 2,100 | 2,055 | 2,060 | 1,991 | 2,018 | Upgrade |
Total Assets | 28,417 | 20,775 | 30,955 | 33,016 | 27,716 | Upgrade |
Accounts Payable | 7.25 | 14.97 | 7.04 | 4.39 | 1.61 | Upgrade |
Other Current Liabilities | 11.17 | 5.53 | 3.51 | 1.57 | 1.03 | Upgrade |
Total Current Liabilities | 18.41 | 20.5 | 10.55 | 5.96 | 2.64 | Upgrade |
Long-Term Deferred Tax Liabilities | 982.2 | - | 968.14 | 1,204 | 566.4 | Upgrade |
Total Liabilities | 1,001 | 20.5 | 978.69 | 1,210 | 569.04 | Upgrade |
Common Stock | 139.09 | 139.09 | 139.09 | 139.09 | 139.09 | Upgrade |
Additional Paid-In Capital | - | 649.96 | 649.96 | 649.96 | 649.96 | Upgrade |
Retained Earnings | - | 1,774 | 1,840 | 1,841 | 1,531 | Upgrade |
Comprehensive Income & Other | 27,277 | 18,191 | 27,347 | 29,175 | 24,827 | Upgrade |
Shareholders' Equity | 27,416 | 20,755 | 29,976 | 31,805 | 27,147 | Upgrade |
Total Liabilities & Equity | 28,417 | 20,775 | 30,955 | 33,016 | 27,716 | Upgrade |
Net Cash (Debt) | 161.75 | 469.96 | 517.3 | 391.46 | 451.53 | Upgrade |
Net Cash Growth | -65.58% | -9.15% | 32.15% | -13.30% | 5.58% | Upgrade |
Net Cash Per Share | 2.32 | 6.76 | 7.44 | 5.63 | 6.49 | Upgrade |
Filing Date Shares Outstanding | 68.5 | 69.55 | 69.55 | 69.55 | 69.55 | Upgrade |
Total Common Shares Outstanding | 68.5 | 69.55 | 69.55 | 69.55 | 69.55 | Upgrade |
Working Capital | 144.22 | 459.99 | 521.04 | 590.81 | 603.46 | Upgrade |
Book Value Per Share | 400.22 | 298.43 | 431.02 | 457.33 | 390.35 | Upgrade |
Tangible Book Value | 27,416 | 20,755 | 29,976 | 31,805 | 27,147 | Upgrade |
Tangible Book Value Per Share | 400.22 | 298.43 | 431.02 | 457.33 | 390.35 | Upgrade |
Buildings | - | 0.07 | 0.07 | 0.07 | 0.07 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.